Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Company Info
SIC2836
Composite FIGIBBG000DR0RZ7
CIK0000072444
IPODec 10, 1981
Sectorbiological products, (no disgnostic substances)
The chart shows the growth of an initial investment of $10,000 in Vaxart, Inc Common Stock, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Vaxart, Inc Common Stock (VXRT) has returned 76.81% so far this year and 96.02% over the past 12 months. Looking at the last ten years, VXRT has achieved an annualized return of -23.60%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
VXRT
1M-19.15%
6M72.80%
YTD76.81%
1Y96.02%
5Y-35.70%
10Y-23.60%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Vaxart, Inc Common Stock (VXRT) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
68.06%
37.09%
-24.38%
-1.61%
2025
1.46%
-21.65%
-18.62%
9.90%
-1.57%
5.56%
-22.92%
5.41%
3.95%
-9.57%
13.50%
-3.78%
2024
104.15%
0.83%
4.00%
-46.26%
15.02%
-18.31%
1.16%
28.64%
0.21%
-9.96%
-21.79%
8.12%
2023
9.09%
-27.83%
-1.73%
7.51%
48.78%
-39.17%
10.76%
0.44%
-10.24%
-10.78%
8.33%
-21.33%
2022
-22.05%
3.46%
-0.40%
-31.09%
5.51%
-4.63%
5.44%
-14.60%
-28.05%
-25.45%
-30.59%
-19.92%
2021
107.53%
-48.93%
-18.38%
75.28%
-33.60%
13.14%
-5.23%
9.15%
-10.77%
-15.60%
17.93%
-19.62%
2020
273.13%
102.11%
-40.20%
51.69%
-5.96%
228.62%
11.12%
-35.33%
18.54%
-24.77%
58.96%
-32.67%
2019
5.13%
-16.10%
13.45%
-63.73%
-10.55%
3.09%
-1.43%
2.14%
-48.71%
-11.36%
3.50%
-1.13%
2018
-37.89%
-3.39%
-0.38%
-0.58%
-41.44%
2.69%
-1.93%
-6.56%
5.40%
5.84%
-41.98%
Performance Indicators
The charts below present risk-adjusted performance metrics for Vaxart, Inc Common Stock (VXRT) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of VXRT compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Vaxart, Inc Common Stock volatility is 5.82%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2024
2023
2022
2021
2020
2019
2018
Liabilities And Equity (USD)
166.39M
91.83M
153.85M
221.17M
152.58M
37.03M
35.23M
Equity Attributable To Parent (USD)
58.93M
57.81M
110.60M
187.53M
123.40M
12.95M
11.24M
Equity Attributable To Noncontrolling Interest (USD)
The article highlights three sub-$5 stocks with positive analyst sentiment and significant upside potential: Grab Holdings (emerging market play with 54% upside target), Vaxart Inc. (clinical-stage biotech with oral vaccine platform and 233% upside), and ThredUp Inc. (online consignment platform with 190% upside target). All three benefit from favorable analyst ratings despite recent pullbacks, with expectations for growth in 2026 as money potentially flows back into small-cap and speculative stocks.
Investing.com•Chris Markoch
AI Insight
Clinical-stage biotech company with Buy rating and $2 price target (233% upside from ~$0.60), developing oral vaccines for influenza, norovirus, and COVID-19 with potential for broader immune response; strong dollar volume inflows (10:1 ratio).
Dynavax reported strong Q3 2025 financial results, with HEPLISAV-B vaccine revenue increasing 13% to $90 million. The company entered an exclusive license agreement with Vaxart for an oral COVID-19 vaccine and authorized a new $100 million share repurchase program.
Benzinga•Prnewswire
AI Insight
Secured a significant licensing deal with Dynavax for their oral COVID-19 vaccine, receiving $25 million upfront and a $5 million equity investment
Dynavax Technologies has entered an exclusive worldwide license agreement with Vaxart to develop and commercialize an oral COVID-19 vaccine candidate, paying $25 million upfront and investing $5 million in equity, with potential future milestone payments.
Benzinga•Prnewswire
AI Insight
Secured significant upfront payment and potential future milestone payments for its oral vaccine technology, while retaining development responsibilities through Phase 2b
Vaxart will present research on its oral pill vaccine candidates for norovirus and COVID-19 at the World Vaccine Congress Europe 2025 in Amsterdam, highlighting advances in its clinical-stage vaccine development platform.
GlobeNewswire Inc.•Vaxart, Inc.
AI Insight
The company is showcasing promising clinical-stage vaccine programs, demonstrating potential advancements in oral vaccine technology for norovirus and COVID-19, with a focus on improving global public health
A group of Vaxart stockholders criticized the company's board for adjourning a special meeting to vote on a reverse stock split, alleging manipulation and delay tactics despite achieving a voting quorum.
GlobeNewswire Inc.•Concerned Vaxart Stockholders
AI Insight
The board is accused of repeatedly delaying stockholder votes, withholding voting results, and potentially manipulating the reverse stock split process against stockholder interests. Stockholders view the board's actions as undermining transparency and corporate governance.
Vaxart has adjourned its 2025 special stockholder meeting to September 19, 2025, providing more time for stockholders to consider recent Board composition changes and potential governance modifications. The reverse stock split proposal was not voted on at the original September 5th meeting.
GlobeNewswire Inc.•Matt Steinberg
AI Insight
The company is seeking additional time and engagement with stockholders, demonstrating transparency and willingness to consider feedback about governance and potential stock actions
Vaxart received a Nasdaq Hearings Panel decision granting an extension to regain compliance with the Nasdaq Bid Price Rule by October 17, 2025, requiring stockholder approval for a reverse stock split by September 5, 2025.
GlobeNewswire Inc.•Vaxart, Inc.
AI Insight
The company is proactively addressing its Nasdaq listing compliance issue by seeking an extension and proposing a reverse stock split, indicating strategic management but facing potential challenges in maintaining its stock price and exchange listing
Vaxart, a clinical-stage biotechnology company, has qualified to trade on the OTCQX Best Market after previously trading on NASDAQ. The company focuses on developing oral recombinant vaccines for various diseases including coronavirus, norovirus, and influenza.
GlobeNewswire Inc.•Otc Markets Group Inc.
AI Insight
The company is expanding its market presence by moving to OTCQX, demonstrating continued market access and highlighting its innovative vaccine development platform focused on oral pill vaccines
Vaxart, a clinical-stage biotechnology company, held its Annual Meeting of Stockholders. Preliminary results show that two proposals were approved and two were rejected by stockholders. The company is evaluating its options regarding the rejected proposals.
GlobeNewswire Inc.•Clear® Verified
AI Insight
The article reports positive clinical data for Vaxart's second-generation vaccine technology, which produced stronger antibody responses than the first-generation technology. Additionally, the company is evaluating its options after some proposals were approved and others were rejected by stockholders, indicating ongoing progress and decision-making.
Vaxart, a clinical-stage biotechnology company, will release topline data from its norovirus Phase I trial and host a conference call to discuss the results.
GlobeNewswire Inc.•Clear® Verified
AI Insight
The article announces positive news about Vaxart's upcoming release of topline data from its norovirus Phase I trial, indicating progress in the company's development of oral recombinant vaccines.
